Heart Test Laboratories announced that the MyoVista wavECG has been selected by the Innovation Value Institute as a technology which can drive the radical transformation of healthcare and has been invited to demonstrate and discuss the MyoVista wavECG at the 4th Digital Health Symposium at the United Nations General Assembly to be held in New York, USA in September 2024. Andrew Simpson, CEO of HeartSciences, said, “We are honored that the MyoVista wavECG has been recognized as a technology with the potential to radically transform healthcare and look forward to our demonstration at the United Nations General Assembly Digital Health Symposium in September. This builds on our recent successes that include increasing support from key opinion leaders and establishing relationships in the UK and Ireland for our technology. It also evidences the enormous commercial opportunity for our AI-ECG products.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSCS:
- HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
- Heart Test Laboratories, Inc. (HSCS) Q4 Earnings Cheat Sheet
- HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
- Heart Test Laboratories announces allowance of U.S. patent for AI-ECG
- Heart Test Laboratories regains compliance with Nasdaq listing requirements